Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (May 2014)
19 slides from Ani Pharmaceuticals's investor presentation, May 29, 2014
Slide 1: Corporate Presentation June 2014
A Specialty Pharmaceutical Company NASDAQ: ANIP HIGH POTENCY DRUGS – NARCOTIC DRUGS – RX LIQUIDS AND TABLETS – CONTRACT MANUFACTURING Corporate Presentation June 2014
Slide 2: Cautionary Statement Concerning Forward-Looking Statements
2 Cautionary Statement Concerning Forward - Looking Statements This presentation may contain forward - looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the Company’s plans, objectives, expectations and in
Slide 3: ANI Mission Statement
3 3 ANI Mission Statement ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. ANI’s mission is to develop, manufacture, and market niche generic pharmaceuticals, focusing on opportunities in p
Slide 4: ANI Overview – Poised for Growth
4 ANI Overview – Poised for Growth ANI Today ▪ Core competencies: marketing and manufacturing ▪ Two manufacturing facilities: narcotics and potent compounds ▪ Experienced management team ▪ Existing business + potential future royalty + new products + potential acquisitions – For the quarter ended Ma
Slide 5: ANI Recent History and Highlights
5 5 ANI Recent History and Highlights 2009 New executive management team: Art Przybyl, CEO and Charlotte Arnold, CFO 2010 New management expands ANI strategy to include ANI labeled Rx products 2011 ANI expands marketed Rx portfolio to seven products through internal development and acquisition 2013
Slide 6: Sales and Marketing / Financial Overview
6 6 Sales and Marketing / Financial Overview
Slide 7: ANI Historical Revenue Growth
7 ANI Historical Revenue Growth 7 $s in millions 39% 42% 43% 33% C ost of sales as a percentage of net revenues, excluding depreciation and amortization
Slide 8: ANI Current Rx Product Portfolio
8 ANI Current Rx Product Portfolio Market Generic Products Position Share (1) EE/MT Tablets #1 75% Fluvoxamine Tablets #1 55% HC Enema #1 85% Metoclopramide Solution #2 31% Opium Tincture #1 75% 8 Branded Products Cortenema TM Reglan Tablets TM (1) Based on Company estimates, and recent IMS and NSP
Slide 9: ANI Rx Portfolio Prescription Volumes
9 ANI Rx Portfolio Prescription Volumes 9 Source: IMS Health
Slide 10: ANI Contract Manufacturing and Royalties
10 ANI Contract Manufacturing and Royalties 10 Current Business ▪ $2.1 million in contract manufacturing and services revenues during the three - month period ended March 31, 2014 ▪ Six customers – Twelve products and sixteen SKUs Future Opportunities ▪ One contract customer awaiting FDA approval –
Slide 11: ANI Financial Highlights
11 ANI Financial Highlights 11 Annual Results - 2013 ($ in millions) Twelve months ended December 31, 2013 December 31, 2012 % Growth Net Revenues $30.1 $20.4 48% Adjusted non - GAAP EBITDA (1) $7.5 $1.5 436% Quarterly Results – 1 st Quarter 2014 ($ in millions) Three months ended March 31, 2014 Mar
Slide 12: Product Development / Business Development Overview
12 12 Product Development / Business Development Overview
Slide 13: ANI Product Development Highlights
13 13 ANI Product Development Highlights Development Pipeline: 46 p roducts in development ▪ Six filed ANDAs, 40 ANDAs in progress – Development partners: Ricon , Sofgen , Sterling ▪ Total combined current market: $2.7 billion (1) (1) Based on Company estimates, and recent IMS and NSP Audit data The
Slide 14: ANI Business Development Highlights
14 14 ANI Business Development Highlights Acquired 31 generic products from Teva , December 2013 Product development partnership with Sofgen , August 2013; expanded partnership, April 2014 Acquired royalty arrangement with Teva , June 2013 Product development partnership with Ricon , June 2011 Acqui
Slide 15: Manufacturing Overview
15 15 Manufacturing Overview
Slide 16: ANI Manufacturing – Main Street Facility
16 16 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of la
Slide 17: ANI Manufacturing – IDC Road Facility
17 17 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight
Slide 18: ANI Summary
18 ANI Summary ANI is an integrated specialty/generic pharmaceutical firm with: ▪ Profitable base business generating organic growth ▪ Well capitalized balance sheet ▪ Experienced management team ANI is focused on: ▪ Internal product development ▪ Partnerships/strategic alliances ▪ Accretive acquisi
Slide 19: U.S. GAAP Reconciliation
19 U.S. GAAP Reconciliation 19 2014 2013 2013 2012 Operating Income Add back Depreciation and amortization 703 145 1,110 567 Add back Stock - based compensation 47 - 36 - Merger - related expenses, not already added back Adjusted non - GAAP EBITDA $4,245 $683 $7,512 $1,454 929 $898 ($42) - 135 5,468
ANI Pharmaceuticals — Investor Presentation (May 2014) on 6ix